CR10822A - Formulacion en polvo del valganciclovir - Google Patents
Formulacion en polvo del valganciclovirInfo
- Publication number
- CR10822A CR10822A CR10822A CR10822A CR10822A CR 10822 A CR10822 A CR 10822A CR 10822 A CR10822 A CR 10822A CR 10822 A CR10822 A CR 10822A CR 10822 A CR10822 A CR 10822A
- Authority
- CR
- Costa Rica
- Prior art keywords
- powder formulation
- dosage forms
- valganciclovir
- valganciclovir powder
- cytomegalovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La presente invencion proporciona nuevas formas farmaceuticas solidas de dosificacion de valganciclovir clorhidrato para la administracion oral, despues de haberse constituido en agua. Estas nuevas formas farmaceuticas de dosificacion son utiles para el tratamiento o control de virus, tales como el virus herpes simplex y el citomegalovirus.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87463406P | 2006-12-13 | 2006-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10822A true CR10822A (es) | 2009-06-25 |
Family
ID=39410167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10822A CR10822A (es) | 2006-12-13 | 2009-05-21 | Formulacion en polvo del valganciclovir |
Country Status (31)
Country | Link |
---|---|
US (6) | US20080146591A1 (es) |
EP (1) | EP2101733B1 (es) |
JP (1) | JP5111517B2 (es) |
KR (1) | KR101116553B1 (es) |
CN (1) | CN101541310B (es) |
AR (1) | AR065541A1 (es) |
AU (1) | AU2007332640B2 (es) |
BR (1) | BRPI0720118B8 (es) |
CA (1) | CA2671470C (es) |
CL (1) | CL2007003564A1 (es) |
CO (1) | CO6220902A2 (es) |
CR (1) | CR10822A (es) |
DK (1) | DK2101733T3 (es) |
ES (1) | ES2391912T3 (es) |
HR (1) | HRP20121033T1 (es) |
IL (1) | IL198854A (es) |
MA (1) | MA31280B1 (es) |
MX (1) | MX2009005921A (es) |
MY (1) | MY152540A (es) |
NO (1) | NO339838B1 (es) |
NZ (1) | NZ577179A (es) |
PE (1) | PE20081578A1 (es) |
PL (1) | PL2101733T3 (es) |
PT (1) | PT2101733E (es) |
RS (1) | RS52457B (es) |
RU (1) | RU2440118C2 (es) |
SI (1) | SI2101733T1 (es) |
TW (1) | TWI341730B (es) |
UA (1) | UA93599C2 (es) |
WO (1) | WO2008071573A2 (es) |
ZA (1) | ZA200903840B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2257294A2 (en) * | 2008-03-07 | 2010-12-08 | Ray W. Exley | Treatment of herpes virus related diseases |
CN102048677B (zh) * | 2009-11-09 | 2014-03-05 | 杭州赛利药物研究所有限公司 | 一种盐酸缬更昔洛韦固体制剂及其制备方法 |
WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
AU2013249708B2 (en) * | 2012-04-20 | 2017-03-16 | Annji Pharmaceutical Co., Ltd. | Cyclopropanecarboxylate esters of purine analogues |
RU2015132902A (ru) | 2013-01-07 | 2017-02-09 | Сам-А Фарм. Ко., Лтд. | Новый быстрорастворимый состав гранул с улучшенной растворимостью |
ES2629103T3 (es) * | 2013-08-02 | 2017-08-07 | Ali Raif Ilaç Sanayi Ve Ticaret Anonim Sirketi | Formulación en polvo de valganciclovir |
CN104055746B (zh) * | 2014-07-12 | 2017-06-30 | 河北仁合益康药业有限公司 | 一种盐酸缬更昔洛韦包衣片剂组合物 |
RU2720805C1 (ru) * | 2019-05-22 | 2020-05-13 | Общество с ограниченной ответственностью "Трейдсервис" | Фармацевтическая композиция валганцикловира |
EP3976198A4 (en) | 2019-05-31 | 2023-07-19 | Viracta Subsidiary, Inc. | METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS |
CN110613718A (zh) * | 2019-09-19 | 2019-12-27 | 湖北科益药业股份有限公司 | 一种缬更昔洛韦组合物 |
CN110934823B (zh) * | 2019-12-27 | 2022-03-01 | 湖北康源药业有限公司 | 一种盐酸缬更昔洛韦口服溶液及制备方法 |
WO2021161317A1 (en) * | 2020-02-12 | 2021-08-19 | Cts Chemical Industries Ltd. | Stable pharmaceutical compositions comprising valgancyclovir and uses thereof |
CN114028347B (zh) * | 2021-11-30 | 2023-05-12 | 海南皇隆制药股份有限公司 | 注射用帕瑞昔布钠及其制备方法 |
CN115569113B (zh) * | 2022-09-19 | 2023-11-10 | 江苏汉晨药业有限公司 | 一种盐酸缬更昔洛韦口服溶液 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR880002139B1 (ko) | 1983-04-08 | 1988-10-17 | 베링거 인겔하임 리미티드 | 경구 투여용 정제의 제조방법 |
US5840891A (en) | 1994-07-28 | 1998-11-24 | Syntex (U.S.A.) Inc. | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative |
US5840890A (en) | 1996-01-26 | 1998-11-24 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
US6365196B1 (en) * | 1997-10-03 | 2002-04-02 | Smithkline Beecham Corporation | Controlled release solid dosage forms of lithium carbonate |
US6221917B1 (en) * | 1997-12-30 | 2001-04-24 | American Home Products Corporation | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
CA2244097A1 (en) * | 1998-08-21 | 2000-02-21 | Bernard Charles Sherman | Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid |
US20020143058A1 (en) * | 2001-01-24 | 2002-10-03 | Taro Pharmaceutical Inductries Ltd. | Process for preparing non-hygroscopic sodium valproate composition |
EP1459739B1 (en) | 2003-03-19 | 2008-01-02 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids |
CA2537132A1 (en) * | 2003-08-28 | 2005-03-10 | Ranbaxy Laboratories Limited | Amorphous valganciclovir hydrochloride |
DE602005008721D1 (de) | 2004-03-10 | 2008-09-18 | Ranbaxy Lab Ltd | Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid |
BRPI0614870A2 (pt) | 2005-08-22 | 2011-04-19 | Novartis Ag | composições farmacêuticas |
-
2007
- 2007-12-03 MX MX2009005921A patent/MX2009005921A/es active IP Right Grant
- 2007-12-03 RS RS20120429A patent/RS52457B/en unknown
- 2007-12-03 NZ NZ577179A patent/NZ577179A/en unknown
- 2007-12-03 RU RU2009126616/15A patent/RU2440118C2/ru active
- 2007-12-03 JP JP2009540707A patent/JP5111517B2/ja active Active
- 2007-12-03 PT PT07847662T patent/PT2101733E/pt unknown
- 2007-12-03 AU AU2007332640A patent/AU2007332640B2/en active Active
- 2007-12-03 WO PCT/EP2007/063151 patent/WO2008071573A2/en active Application Filing
- 2007-12-03 MY MYPI20092409 patent/MY152540A/en unknown
- 2007-12-03 BR BRPI0720118A patent/BRPI0720118B8/pt active IP Right Grant
- 2007-12-03 PL PL07847662T patent/PL2101733T3/pl unknown
- 2007-12-03 SI SI200731076T patent/SI2101733T1/sl unknown
- 2007-12-03 EP EP07847662A patent/EP2101733B1/en active Active
- 2007-12-03 UA UAA200907074A patent/UA93599C2/ru unknown
- 2007-12-03 CN CN2007800443008A patent/CN101541310B/zh active Active
- 2007-12-03 CA CA2671470A patent/CA2671470C/en active Active
- 2007-12-03 ES ES07847662T patent/ES2391912T3/es active Active
- 2007-12-03 DK DK07847662.9T patent/DK2101733T3/da active
- 2007-12-03 KR KR1020097014059A patent/KR101116553B1/ko active IP Right Grant
- 2007-12-10 CL CL200703564A patent/CL2007003564A1/es unknown
- 2007-12-11 AR ARP070105524A patent/AR065541A1/es not_active Application Discontinuation
- 2007-12-11 TW TW096147281A patent/TWI341730B/zh active
- 2007-12-11 US US12/001,290 patent/US20080146591A1/en not_active Abandoned
- 2007-12-12 PE PE2007001774A patent/PE20081578A1/es not_active Application Discontinuation
-
2009
- 2009-05-20 IL IL198854A patent/IL198854A/en active IP Right Grant
- 2009-05-21 CR CR10822A patent/CR10822A/es unknown
- 2009-05-22 CO CO09053156A patent/CO6220902A2/es not_active Application Discontinuation
- 2009-06-02 ZA ZA200903840A patent/ZA200903840B/xx unknown
- 2009-06-05 MA MA31956A patent/MA31280B1/fr unknown
- 2009-06-11 NO NO20092254A patent/NO339838B1/no not_active IP Right Cessation
-
2012
- 2012-12-14 HR HRP20121033TT patent/HRP20121033T1/hr unknown
-
2013
- 2013-02-05 US US13/759,348 patent/US8889109B2/en active Active
-
2014
- 2014-10-31 US US14/529,839 patent/US9642911B2/en active Active
-
2017
- 2017-04-05 US US15/479,544 patent/US20170266286A1/en not_active Abandoned
- 2017-12-19 US US15/846,991 patent/US20180153998A1/en not_active Abandoned
-
2018
- 2018-12-19 US US16/225,433 patent/US11185588B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10822A (es) | Formulacion en polvo del valganciclovir | |
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
PH12015502780B1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
MX2012012438A (es) | Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina. | |
MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
BR112015018168A2 (pt) | inibidores de rock suaves | |
EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
CL2015001374A1 (es) | Compuestos derivados de 2-(metilamino)-n-(2-oxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3il)propanamida; composicion farmaceutica; y su uso en el tratamiento terapeutico o profilactico del cancer. | |
IL218277B (en) | Tetracycline compounds, pharmaceutical preparations containing them and their use for the preparation of medicines for the treatment and prevention of infection | |
WO2012030914A8 (en) | 4-azolylaminoquinazoline derivatives and methods of use thereof | |
MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine |